NBIX

TentativeAI Memo

Neurocrine Biosciences

As of 2026-09-30/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-30 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

VYKAT XR uptake after the Soleno acquisition • 2026-12-31

Base target: $145 / p=50% prob

Biggest risk

VYKAT XR must justify a $2.9 billion acquisition while clinical readouts remain binary. Q2 GAAP R&D rose to $327 million from $244 million a year earlier, and cash, equivalents and marketable securities fell to $482 million from $2.543 billion at 2025 year-end. [#SEC-8K-2026-07-30]

Invalidation

Break below $105 or thesis failure.

What would change my mind?

Q2 revenue grew 39% year over year to $959 million, supported by INGREZZA, CRENESSITY and newly acquired VYKAT XR. Sustained uptake plus successful 2027 clinical readouts could support a higher valuation. [#SEC-8K-2026-07-30]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-30

Base target

$145

p=50%

Bull target

$180

p=25%

Bear target

$105

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

INGREZZA sales against raised 2026 guidance
Osavampator Phase 3 readout
Direclidine Phase 3 readout

BearKey bullets

Higher R&D spending and the post-acquisition reduction in cash narrow near-term financial flexibility, although Neurocrine reported $1 billion of available revolving-credit capacity at June 30.
[#SEC-8K-2026-07-30]
INGREZZA growth or CRENESSITY reimbursement may slow relative to Q2 trends.

WatchKey bullets

VYKAT XR uptake after the Soleno acquisition

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $145 (p=50%)

Target spread vs base: +24% / -28%

Scenario probabilities

Bull Target: $180 (p=25%)Base Target: $145 (p=50%)Bear Target: $105 (p=25%)

Commentary

Operating evidence is constructive, but the deterministic directional prior is neutral and recent trusted coverage, analyst revisions and verified post-release price reaction are unavailable. The sentiment fields set to zero are unavailable inputs, not observed neutral readings. A September 28 8-K excerpt addresses Roberts's compensation rather than commercial or clinical performance, so it does not change the thesis. [#8-K-2026-09-28]

As of 2026-09-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

INGREZZA sales against raised 2026 guidance
Osavampator Phase 3 readout
Direclidine Phase 3 readout

Scenarios

Bull Target (Scenario probability)

$180 / p=25% prob

Base Target (Scenario probability)

$145 / p=50% prob

Bear Target (Scenario probability)

$105 / p=25% prob

Analysis 2026-09-30 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
VYKAT XR uptake after the Soleno acquisition
VYKAT XR generated $54 million after the May 18 acquisition close, versus $94 million on a pro-forma full-quarter basis. Later sales and reimbursement data will test the $2.9 billion acquisition rationale; the checkpoint date is an estimate. [#SEC-8K-2026-07-30]
Prob 60.00% • Move 7.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

INGREZZA sales against raised 2026 guidance
2026-12-31
Q2 INGREZZA sales rose 15% to $716 million, and Neurocrine raised full-year sales guidance to $2.825–$2.875 billion. Subsequent sales will test whether prescription growth sustains that increase. The year-end date is a monitoring estimate, not an announced reporting date. [#SEC-8K-2026-07-30]
Prob 65% • Move 6% • Priced-in 65%

Long-term Catalysts

Months to a year

Osavampator Phase 3 readout
2027-12-31
Management identified a 2027 Phase 3 readout for osavampator in major depressive disorder. The precise readout date and outcome are not established; December is a year-end placeholder. [#SEC-8K-2026-07-30]
Prob 50% • Move 12% • Priced-in 30%
Direclidine Phase 3 readout
2027-12-31
Management also identified a 2027 Phase 3 readout for direclidine in schizophrenia. Clinical efficacy and safety remain unproven; December is a year-end placeholder, not company timing guidance. [#SEC-8K-2026-07-30]
Prob 50% • Move 12% • Priced-in 30%

Risks

Higher R&D spending and the post-acquisition reduction in cash narrow near-term financial flexibility, although Neurocrine reported $1 billion of available revolving-credit capacity at June 30. [#SEC-8K-2026-07-30]
INGREZZA growth or CRENESSITY reimbursement may slow relative to Q2 trends. [#SEC-8K-2026-07-30]
Osavampator and direclidine Phase 3 results could disappoint; only the 2027 readout year is established. [#SEC-8K-2026-07-30]
VYKAT XR integration and uptake may fail to justify the $2.9 billion Soleno purchase. [#SEC-8K-2026-07-30]

Peers

Symbol	Summary
JAZZ	The closer neuroscience commercial comparator: Jazz markets treatments for epilepsy and sleep disorders, making specialist-prescriber access and CNS franchise durability useful comparisons with Neurocrine. Its indications differ, and its oncology business limits whole-company comparability. Jazz medicines
ASND	The closer rare-endocrine-disease comparator: Ascendis markets endocrine therapies and develops additional rare-disease programs, making launch uptake, reimbursement and pipeline investment relevant comparisons with CRENESSITY and VYKAT XR. Its products and technology differ from Neurocrine's. Ascendis products Ascendis pipeline

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-30

Loading AI feed…

Symbol

Summary

JAZZ

The closer neuroscience commercial comparator: Jazz markets treatments for epilepsy and sleep disorders, making specialist-prescriber access and CNS franchise durability useful comparisons with Neurocrine. Its indications differ, and its oncology business limits whole-company comparability. Jazz medicines

ASND

The closer rare-endocrine-disease comparator: Ascendis markets endocrine therapies and develops additional rare-disease programs, making launch uptake, reimbursement and pipeline investment relevant comparisons with CRENESSITY and VYKAT XR. Its products and technology differ from Neurocrine's. Ascendis products Ascendis pipeline